Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting

TEL AVIV, Israel, Nov. 27, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that Dr. Carol L. Brosgart, Clinical Professor of Medicine, Epidemiology and Biostatistics, University of California, San Francisco (UCSF), a member of Galmed's board of directors, will present at the 22nd biennial HEP DART meeting, to be held at Kona, Hawaii, December 3-7, 2017.

Dr. Brosgart's presentation entitled: "Aramchol for NASH and beyond: From Scientific Rationale to Clinical Development" will provide the foundations of the ARRIVE and ARREST clinical studies which are expected to report topline data in the first and second quarters of 2018, respectively.

Dr. Brosgart's Presentation Details:

Date: Thursday, December 7, 2017
Time: 09:00am HST
Location: Fairmont Orchid Hotel, Kona, Hawaii

About the HEP DART 2017 Meeting

The focus of HEP DART is to assemble clinicians, medical professionals, nurses, researchers and basic scientists together to advance knowledge of the ongoing drug development processes in the treatment of viral hepatitis, NASH, and co-infections. HEP DART meeting  uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in hepatology (including viral hepatitis, NASH, and co-infections).

About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)

Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol™'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in 248 subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed also sponsors the ARRIVE Study, a proof-of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol™ in 50 patients with HIV-associated NAFLD and lipodystrophy. The ARRIVE Study is an investigator-initiated trial, conducted at the University of California San Diego by Professor Rohit Loomba. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591, respectively.

SOURCE Galmed Pharmaceuticals Ltd.